Is There Pathological Uniformity between the Periphery and Center of a Gastrointestinal Stromal Tumor?

Choi, S.; Lee, Kwan Hong; Yoo, Chan Kyoo; Yoon, Jin‐Kook; Jang, Keum‐Il; Kim, Youn Jeong; Lee, Hang Lak

doi:10.3390/jcm10040687

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, no significant association was found between risk and age groups or gender. This is in line with some literature suggesting that while age and gender may influence the incidence and prevalence of GISTs, their impact on the risk or prognosis of these tumors is less clear [23,24] . However, contradictory findings exist, with a few studies suggesting a worse prognosis for older patients or a particular gender [25,26] .…”

Section: Discussionsupporting

confidence: 91%

Gastrointestinal stromal tumors: Clinicopathological correlations

Mikhlif,

Al-Khafaji

2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

Background: Histological, genetic, and anatomical characteristics distinguish gastrointestinal stromal tumours (GISTs) from other neoplasms. GISTs, the most common gastrointestinal (GI) mesenchymal tumours, occur 7 to 19 times per million annually. This study discusses GIST clinicopathological relationships and how they might be used to optimize risk stratification and adjuvant treatment. Method: Cross-sectional research of 99 gastrointestinal stromal tumour patients from January 2019 to January 2023 at Medical city/GIT and hepatology teaching hospital and Medical city teaching complex/teaching laboratories/histopathology department. All patients were queried about age (years), gender, tumour location and size, mitotic rate (high or low), and cancer risk group (high, moderate, low, and very low). Results: Mean patient age 52.5 ± 13 years old. 32.3% of patients over 60, 24.3% 51-60. Males 54.5%, females 45.5%. Patients 52.5% had lower Mitotic rate 550 HPF, 49.5% are high risk. 58.59% of patients have stomach tumours, 22.22% have large bowel tumours, and 19.19% have small intestine tumours. Mitotic rate is associated with risk; 97.9% of high Mitotic rates are high risk. Site and danger are also associated: 24.1% of stomach tumours are high risk while 72.7% of small intestinal tumours are extremely low risk. No substantial connection exists between age and gender and risk. Risk category affects tumour size: high risk has large tumours, whereas low risk has small tumours. Conclusion: Our analysis confirms key GIST prognostic correlations. We confirmed that high mitotic rate, tumour location, and size influence risk category, validating previous research. Age and gender affected GIST prevalence, but not risk category in our group. These results emphasise the need for extensive risk classification in GISTs for effective patient care and need additional study of populationspecific demographics and features.

show abstract

Section: Discussionsupporting

confidence: 91%

Gastrointestinal stromal tumors: Clinicopathological correlations

Mikhlif,

Al-Khafaji

2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

show abstract

Gastric defect closure after endoscopic full-thickness resection: the closing while dissecting technique

et al. 2022

View full text Add to dashboard Cite

Value of 18F-FDG PET/CT for differentiating diagnosis between malignant and benign primary gastric gastrointestinal mesenchymal tumors: a single-center retrospective study

Li¹,

Lin²,

Tang³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Malignant primary gastric gastrointestinal stromal tumors (gGISTs) without treatment with imatinib are prone to bleeding and peritoneum implantation during operation. Therefore, preoperative assessment of the malignant potential of gGIST is essential. The use of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) combined with computed tomography (PET/CT) as a non-invasive tool for diagnosis, staging and prognosis evaluation in oncology, may also be useful for gGISTs. In the present study, we analyzed the value of 18 F-FDG PET-CT in assessing the malignant potential of gGISTs before treatment.Methods: Patients who were diagnosed with gGIST by pathology and underwent 18 F-FDG PET/CT at the same time were collected. The clinicopathological features of 26 patients with gGISTs were retrospectively analyzed at last. The gGIST risk classification was graded according to the US National Institutes of Health (NIH) GIST risk classification criteria [2008]. Lesions were classified as malignant group (moderate-or high-risk category) and benign group (low-or very low-risk category) according to pathology. The relationship between the maximal standard uptake value (SUVmax) and GIST risk category, tumor diameter, Ki-67 index, and mitotic count was analyzed. The cut-off level of SUVmax for the diagnosis of malignant gGIST with the highest sensitivity was calculated based on the receiver-operating characteristic (ROC) curve. Results:The SUVmax, tumor diameter, Ki-67 index, and mitotic count of the 26 gGIST patients were 5. 90±4.49, 7.40±4.92 cm, 7.62%±11.76%, (5.96±3.19)/50 high-power field (HPF), respectively. SUVmax was significantly correlated with GIST risk category, Ki-67 index, and mitotic count (r=0.855, 0.860, and 0.690, all P<0.01) but not with tumor diameter (r=0.383, P=0.054). The SUVmax of gGIST was 7.00±4.57 in the malignant group (moderate or high NIH risk category in 20 patients), which was significantly different from that (2.25±0.77) in the benign group (low or extremely low NIH risk category in 6 patients) (t=4.566, P<0.01). ROC curve analysis showed that a SUVmax cut-off of 2.60 was most sensitive for predicting malignant gGIST. When the area under the curve was 0.967, the sensitivity was 100% and the specificity was 83.3%.Conclusions: SUVmax may be used as a complementary indicator for predicting the malignant potential of gGISTs before treatment.

show abstract

Is There Pathological Uniformity between the Periphery and Center of a Gastrointestinal Stromal Tumor?

Cited by 3 publications

References 18 publications

Gastrointestinal stromal tumors: Clinicopathological correlations

Gastrointestinal stromal tumors: Clinicopathological correlations

Gastric defect closure after endoscopic full-thickness resection: the closing while dissecting technique

Value of 18F-FDG PET/CT for differentiating diagnosis between malignant and benign primary gastric gastrointestinal mesenchymal tumors: a single-center retrospective study

Contact Info

Product

Resources

About